NCT07001865Enrolling by invitation
Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia
Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia: A Cohort Study With Mediation Analysis
Source: ClinicalTrials.gov · Last updated 3 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Although metabolically healthy obesity (MHO) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperuricemia remains unclear. This study examined the associations between MHO and other metabolic-obesity phenotypes with MASLD and hyperuricemia, and explored the mediating roles of metabolic indicators.This study included 11,712 and 13,846 participants from a health examination cohort at the First Affiliated Hospital of Ningbo University for MASLD and hyperuricemia analyses, respectively. Participants were classified into four metabolic-obesity phenotypes, with MHO defined as obesity without metabolic syndrome components. The outcomes were MASLD and hyperuricemia. Cox regression and mediation analyses were conducted to assess associations and mediating effects.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 17040 (estimated)
- First submitted
- 25 May 2025
- Start date
- 1 Apr 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Ningbo No. 1 Hospital
- Diseases
- Obesity, Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07001865
What you commit to
- Study type: Observational
- Planned participants: 17040
- From 1 Apr 2025 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Missing data on height, weight, or components of the metabolic syndrome ;
- Baseline diagnosis of MASLD or any other liver diseases
Other
- Underweight status at baseline, defined as BMI \< 18.5 kg/m² ；
- Baseline diagnosis of hyperuricemia
Who the study is looking for
- Underwent comprehensive health examinations at the Physical Examination Center of the First Affiliated Hospital of Ningbo University between 2017 and 2024;
- Aged 18 years or older at baseline;
- Completed an abdominal ultrasound examination during the health check-up.
Age in the registry: 18 years to 100 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000, Ningbo, Zhejiang Province 315000 Recruiting Coordinator of this site? Confirm its status | Ningbo | China | Unknown status |
Related publications
- Metabolically healthy obesity increases the risks of MASLD and hyperuricemia: a cohort study with mediation analysis.BMC Endocr Disord · 2025 · PMID 41310554
This page is information, not medical advice. Discuss any trial with your doctor.